Paracetamol maker Granules India's quarterly profit drops on supply backlog
Aug 12 (Reuters) - Paracetamol maker Granules India GRAN.NS reported a first-quarter profit fall on Tuesday, as a supply backlog hit sales.
Consolidated profit fell 16.3% to 1.13 billion rupees ($12.9 million) for the quarter ended June 30, and revenue grew 2.6% to 12.1 billion rupees.
The Hyderabad-based drugmaker's North America business, which accounts for more than three-fourths of its revenue, grew 7% year-on-year, while revenue from Europe rose 12%.
But that was not enough to cushion the 30% fall in revenue from outside these top two markets of the company.
For further earnings highlights, click (Full Story).
KEY CONTEXT
Granules holds a 30% global market share of the paracetamol drug, which is used to treat fever and moderate pain. It supplies the drug as an active pharmaceutical ingredient (API) as well as in finished dosage form.
The company said manufacturing at its Gagillapur facility in Telangana was impacted following an adverse U.S. Food and Drug Administration review last year.
Indian drugmakers are also grappling with pricing pressure in the key North American market due to intense competition, while also bracing for a potential hike in U.S. tariffs on pharmaceutical products from India.
PEER COMPARISON
| Valuation (next 12 months) | Estimates (next 12 months) | Analysts' sentiment | ||||||||
| RIC | PE | EV/EBITDA | Price/Sales | Revenue growth | Profit growth | Mean rating* | # of analysts | Stock to price target** | Div yield (%) | |
| Granules India Ltd | GRAN.NS | 17.35 | 9.79 | NULL | 14.69 | 21.00 | Strong Buy | 4 | 0.73 | 0.34 |
| Alivus Life Sciences Ltd | ALIV.NS | 20.01 | 13.83 | NULL | 10.54 | 10.53 | Strong Buy | 3 | 0.73 | 2.41 |
| Laurus Labs Ltd | LAUL.NS | 70.99 | 27.98 | NULL | 16.49 | 58.07 | Hold | 12 | 1.13 | 0.15 |
| Divi's Laboratories Ltd | DIVI.NS | 55.31 | 39.74 | 14.70 | 14.38 | 19.44 | Hold | 23 | 0.94 | 0.51 |
Recent news on Granules India
See all newsGranules India profit surges as higher sales outweigh cost pressures
Brief: Granules India Q2 Consol Profit 1.82 Billion Rupees
Brief: Granules Says Incorporated Wholly Owned Subsidiary Triton Farmaceutica S.A. De C.V. In Mexico
Brief: Granules Promoter Group Pays 10.93 Billion Rupees For Preferential Issue
Granules India falls after key shareholder trims stake